ERAS Quote, Financials, Valuation and Earnings

Atea Pharmaceuticals, Inc. has a net margin of -- compared to Erasca, Inc.'s net margin of --. Erasca, Inc.'s return on equity of -32.03% beat Atea Pharmaceuticals, Inc.'s return on equity of -36.97%.

Erasca, Inc. has a consensus price target of $5.00, signalling upside risk potential of 52.91%. On the other hand Atea Pharmaceuticals, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 89.27%. Given that Atea Pharmaceuticals, Inc. has higher upside potential than Erasca, Inc., analysts believe Atea Pharmaceuticals, Inc. is more attractive than Erasca, Inc..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Atea Pharmaceuticals, Inc. has a beta of 0.159, suggesting its less volatile than the S&P 500 by 84.143%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atea Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. Atea Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than Atea Pharmaceuticals, Inc. quarterly revenues of --. Erasca, Inc.'s net income of -$30.6M is higher than Atea Pharmaceuticals, Inc.'s net income of -$42M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while Atea Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus 0.84x for Atea Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Immuneering Corp. has a net margin of -- compared to Erasca, Inc.'s net margin of --. Erasca, Inc.'s return on equity of -32.03% beat Immuneering Corp.'s return on equity of -78.54%.

Erasca, Inc. has a consensus price target of $5.00, signalling upside risk potential of 52.91%. On the other hand Immuneering Corp. has an analysts' consensus of $16.83 which suggests that it could grow by 163.02%. Given that Immuneering Corp. has higher upside potential than Erasca, Inc., analysts believe Immuneering Corp. is more attractive than Erasca, Inc..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immuneering Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuneering Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. Immuneering Corp. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than Immuneering Corp. quarterly revenues of --. Erasca, Inc.'s net income of -$30.6M is lower than Immuneering Corp.'s net income of -$15M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while Immuneering Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus 323.21x for Immuneering Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Prelude Therapeutics, Inc. has a net margin of -- compared to Erasca, Inc.'s net margin of -303.46%. Erasca, Inc.'s return on equity of -32.03% beat Prelude Therapeutics, Inc.'s return on equity of -106.36%.

Erasca, Inc. has a consensus price target of $5.00, signalling upside risk potential of 52.91%. On the other hand Prelude Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 173.97%. Given that Prelude Therapeutics, Inc. has higher upside potential than Erasca, Inc., analysts believe Prelude Therapeutics, Inc. is more attractive than Erasca, Inc..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prelude Therapeutics, Inc. has a beta of 1.065, suggesting its more volatile than the S&P 500 by 6.517%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prelude Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. Prelude Therapeutics, Inc. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than Prelude Therapeutics, Inc. quarterly revenues of $6.5M. Erasca, Inc.'s net income of -$30.6M is lower than Prelude Therapeutics, Inc.'s net income of -$19.7M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while Prelude Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus 9.85x for Prelude Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ProKidney Corp. has a net margin of -- compared to Erasca, Inc.'s net margin of -16517.51%. Erasca, Inc.'s return on equity of -32.03% beat ProKidney Corp.'s return on equity of -42.51%.

Erasca, Inc. has a consensus price target of $5.00, signalling upside risk potential of 52.91%. On the other hand ProKidney Corp. has an analysts' consensus of $5.40 which suggests that it could grow by 130.77%. Given that ProKidney Corp. has higher upside potential than Erasca, Inc., analysts believe ProKidney Corp. is more attractive than Erasca, Inc..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProKidney Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProKidney Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. ProKidney Corp. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than ProKidney Corp. quarterly revenues of $217K. Erasca, Inc.'s net income of -$30.6M is higher than ProKidney Corp.'s net income of -$35.8M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while ProKidney Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus 411.04x for ProKidney Corp.. Usually stocks with elevated PS ratios are considered overvalued.